ISRCTN18643079已完成未知
The role of an over the counter topical containing camellia sinensis in the cosmetic management of skin scars
niversity of Manchester0 个研究点目标入组 62 人开始时间: 2018年7月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 62
研究概览
简要总结
2019 Results article in https://pubmed.ncbi.nlm.nih.gov/30822414/ (added 03/08/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 16 years or older
- •2. Able to fully understand study requirements and attend all follow-up visits (in the opinion of the investigator)
- •3. Weigh between 40 and 150 kg with a body mass index 20-35 kg/m² (as described in the Quetelet’s index – weight (kg)/height² (m))
排除标准
- •1. Known allergy to any components of the topical formulation
- •2. History or evidence of keloid scarring or fibrotic disorders (self reported or determined by physical examination)
- •3. Pregnant or planning to conceive within the next 3 months
- •4. Chronic or active skin disorder considered to adversely affect the scar healing by the investigator
- •5. Likely healing impairment due to a significant medical condition such as renal, hepatic, haematological, neurological or immune disease, including rheumatoid arthritis, chronic renal impairment, diabetes mellitus, significant hepatic impairment, inadequately or uncontrolled congestive heart failure, malignancy (diagnosed or treated within the past 5 years) or immunosuppressive, radiation or chemotherapy within the last three months.
- •6. Receiving anticoagulant therapy, systemic steroids, hormone replacement therapy or any investigational drugs, or have taken any in the previous month prior to Day 0
- •7. Evidence of drug abuse
- •8. Had or are known to have serum hepatitis or are carriers of hepatitis B surface antigen, hepatitis B core antibodies or hepatitis C antibodies (previous vaccination against hepatitis B or C is not excluded)
- •9. Previously had a positive result to the HIV antibody test, or admit to belong in a high risk group
- •10. Allergic to other amide local anaesthetics
- •Subjects who have been involved in other studies in the past two months prior to Day 0 must discuss the exact details of the previous studies prior to a decision being made of eligibility for inclusion in this trial.
研究者
相似试验
已完成
不适用
The role of an over-the-counter green tea extract in scarring: Priming the skin prior to injurySkin scarringSkin and Connective Tissue DiseasesISRCTN70155584niversity of Manchester40
已完成
不适用
Skin antiseptic trial for insertion of central venous catheters in neonatesSpecialty: Children, Primary sub-specialty: NeonatalInfections and InfestationsCatheter infectionISRCTN82571474orfolk and Norwich University Hospitals NHS Foundation Trust116
已完成
不适用
Efficacy and tolerability of a topical skin-lightening cosmetic product combination on facial dyspigmentation compared with 4% hydroquinoneMild to moderate facial dyspigmentation due to melasma, but otherwise healthy skinSkin and Connective Tissue DiseasesISRCTN33310512ISISPHARMA43
进行中（未招募）
不适用
Efficacy and tolerability of a new topical formulation of Acyclovir gel (Acyclorir Liquipatch) given 3 times/day in the treatment of herpes simplex labialis. An open-label, blind controlled, randomised, multicenter, controlled clinical trial versus active reference formulation (Acyclovir 5% cream) given 5 times/day. A superiority trial. - NDEUCTR2008-005835-14-ITMIPHARM
已完成
4 期
Improving the efficacy of anti-hair loss drug treatments with a cosmetic lotion containing caffeine, taurine and growth factorsAndrogenic alopecia in men or women (FAGA) candidate for specific drug treatment (i.e. topical minoxidil in men or women or oral finasteride in men)Skin and Connective Tissue DiseasesISRCTN10404684Difa Cooper (Italy)60